SFMBT2 and prostate cancer: In contrast, SFMBT2 expression of prostate cancer patient's specimens was low in 60.4 % (32/53 cases), moderate in 32.1% (17/53 cases), and high in 7.5% (4/53 cases) (Supplementary Table S6).